This review article focuses on the most significant cardiovascular complications in dialysis patients [sudden cardiac death (SCD), acute coronary syndromes, heart failure, and atrial fibrillation].
INTRODUCTION
Cardiovascular complications are the leading cause of morbidity and mortality among dialysis patients. This review article will focus on the most common and significant complications, namely sudden cardiac death (SCD), acute coronary syndromes (ACS), heart failure, and atrial fibrillation.
SUDDEN CARDIAC DEATH
SCD is traditionally defined as 'death from a cardiac cause within one hour from symptom onset in an otherwise well individual' [1] . In practice, unwitnessed death without alternative cause is also frequently categorized as SCD. However, the latter category is likely to include many deaths that are sudden but are caused by stroke, embolism, or causes other than a fatal, primary arrhythmia. Nevertheless, as commonly defined, SCD appears to be responsible for the majority of all deaths on dialysis. SCD accounted for approximately 25% of all deaths in dialysis patients in the 2010 United States Renal Data System (USRDS) report [2] . Findings in a post-hoc analysis of the EVOLVE trial, a large randomized study enrolling 3883 hemodialysis patients, showed that cardiovascular causes were responsible for 54% of deaths and SCD accounted for 24.5% [3] . Similar event rates have been observed
Primary event in sudden cardiac death
The pathophysiology of SCD in dialysis patients has not been elucidated. As noted above, an arrhythmic event may not be the underlying mechanism in at least a minority of cases. Furthermore, whether the majority of arrhythmic deaths are due to shockable rhythms such as ventricular tachycardia and ventricular fibrillation as opposed to nonshockable rhythms such as asystole or bradycardia is currently unknown.
To wit, a retrospective observational study including hemodialysis patients using a wearable cardioverter defibrillator following an initial cardiac arrest identified 75 patients who experienced at least one SCD event [7] . Sixty-four percent of the initial rhythms were ventricular tachycardia and 14% ventricular fibrillation. However, ventricular events could be over-represented in this cohort because of selection bias. Conversely, a prospective study from Australia enrolled 50 stable hemodialysis patients with left ventricular ejection fraction (LVEF) of at least 35% and no history of syncope or ventricular tachyarrhythmias [8 & ]. An implantable cardiac monitor was used for continuous ECG monitoring, and arrhythmic events were automatically recorded if they fulfilled certain predefined criteria. Five SCD occurred after a mean follow-up of 12 months. Although one patient experienced a sustained ventricular tachycardia, the others experienced severe bradycardia with ensuing asystole as the terminal event. This small study suggests that bradycardia and asystole (primary or secondary) rather than ventricular tachyarrhythmia is the electrical event underlying the majority of SCDs. However, it should be recognized that noncardiac deaths such as massive stroke, hemorrhage, or embolism ultimately lead to terminal asystole, and electronic monitoring alone cannot distinguish between primary asystole causing death and terminal asystole from noncardiac death.
Similarly, the MiD study (NCT01779856) enrolled 81 patients with stage 5 chronic kidney disease (CKD) on hemodialysis or expected to initiate hemodialysis within 2 months [9 ]. A loop recorder was implanted, and follow-up continued for a maximum of 12 months. The primary objective was to estimate the incidence of clinically significant arrhythmias and characterize those arrhythmic events. Although final results are pending, preliminary data presented at the American Society of Nephrology meeting in 2014 suggested that bradycardia and asystole were much more frequently detected than the sustained ventricular tachycardia [10].
Risk factors
Risk factors such as coronary artery disease (CAD), heart failure with reduced ejection fraction, or LV hypertrophy are highly prevalent among dialysis patients [3, 11] and may provide an ideal myocardial substrate for the propagation of arrhythmia when triggered by inciting factors that are common, such as metabolic abnormalities, electrolyte and fluid shifts, and ischemia that occur during dialysis or during the interdialytic interval [1] .
Dialysate potassium concentration was examined in a large case-control study [12] . Low potassium dialysate (<2 mmol/l) was independently associated with SCD in a multivariable logistic regression model. The risk became more pronounced as predialysis serum potassium decreased. Dialysate calcium of less than 2.5 mmol/l was also independently associated with SCD in adjusted models [13] .
Hemodialysis itself has also been associated with acutely reduced myocardial blood flow, even in patients without angiographically significant stenosis of the coronary vessels [14] . Whether dialysisinduced ischemic myocardial stunning can trigger a malignant arrhythmia or is rather a predisposing factor contributing in the development of heart
KEY POINTS
Bradycardia and asystole (primary or secondary) rather than ventricular tachyarrhythmias may be the dominant electrical events underlying sudden cardiac death.
Retrospective data on ICDs for primary prevention in dialysis patients do not show definitive benefits.
CABG is associated with a higher short-term mortality (30 days or in hospital) compared with PCI but appears to be superior to PCI for long-term mortality (at least 1 year) and for cardiac events (defined as myocardial infarction or repeat revascularization), at least in those with acceptable surgical risks.
Heart failure is common in dialysis but dialysis-related heart failure should be distinguished from structural causes. The Acute Dialysis Quality Initiative XI Workgroup proposed a functional classification system for heart failure in ESRD based on the New York Heart Association functional classes that may be useful in this regard. AF is extremely common in dialysis patients but whether anticoagulation should be broadly recommended is uncertain. Better data on the role of traditional and novel anticoagulants are sorely needed. failure in dialysis patients is uncertain but seems probable. Lastly, volume shifts may lead to atrial and ventricular stretch from predialysis volume overload or ischemia when rapid ultrafiltration leads to underfilling and hypotension. Whether volume shifts cause SCD is uncertain but associations between rapid ultrafiltration and the risk of death suggest that this may be possible [15] .
Prevention of sudden cardiac death
Implantable cardioverter defibrillators (ICDs) are recommended in patients with preserved renal function for secondary or primary prevention of SCD (when LVEF is severely reduced) [16] . Evidence is lacking in dialysis patients. However, use of ICDs is increasing in the United States, especially for primary prevention [17] .
A retrospective evaluation of USRDS data showed that long-term dialysis patients who had an ICD for likely secondary prevention had an estimated 14% mortality decrease compared with propensity-matched controls [17] . However, the survival curves converged at 3 years of follow-up ( Fig. 1 ). Furthermore, the infection rate was elevated; 98.8 events per 100 patient-years during the first year and 63.9 thereafter, and bacteremia incidence was almost 52 cases per 100 patient-years. All-cause mortality was very high in this cohort (45 deaths per 100 patient-years), and 38% of deaths were attributed to arrhythmias despite ICD insertion.
A retrospective cohort study including all dialysis patients who received an ICD between 2006 and 2007 for primary prevention for an evidence-based indication showed that there was no significant difference in 1-year and 3-year mortality rates between ICD-treated patients and propensitymatched controls [18 & ]. The ICD2 study is a randomized controlled trial (RCT) that will prospectively evaluate the use of ICDs for SCD prevention in dialysis patients (ISRCTN 20479861) [19] . The WED-HED study is an RCT evaluating the impact of a wearable cardioverter defibrillator for SCD prevention in incident dialysis patients (NCT02481206). Both studies are currently recruiting participants.
Other interventions have been evaluated in an attempt to lower the risk of SCD in end-stage renal disease (ESRD). Although beneficial in the general population, b-blockers were not associated with reduced incidence of SCD in a post-hoc analysis of the HEMO study [20] , but a small randomized study of carvedilol in dialysis patients with heart failure did detect a reduction in cardiovascular deaths and a trend toward a reduction in SCD [21] . Other modifiable practices associated with SCD, as identified in the DOPPS trial, include the dialysate potassium concentration (>2.5 mmol/l), the dialysis prescription (treatment time !210 min, Kt/V ! 1.2), the ultrafiltration volume ( 5.7%), or amiodarone avoidance [15] , but each remains unproven.
ACUTE CORONARY SYNDROMES AND MYOCARDIAL REVASCULARIZATION
ACS is a frequent cardiovascular event in dialysis patients. According to USRDS data, approximately 17% of deaths in ESRD are attributable to ACS. CAD prevalence in the same population was 36%, but some estimates suggest that more than 60% of new dialysis patients have evidence of coronary atherosclerosis [22, 23] .
Results from the Global Registry of Acute Coronary Events (GRACE) registry showed that non-ST segment elevation myocardial infarction (MI) is the most common presentation for ACS in dialysis patients [24] . Whether this represents demand ischemia (MI type 2) or is related to atherosclerotic plaque rupture is still unclear. Despite the high prevalence of non-ST compared with ST segment elevation MI, mortality rates are very high -59% at 1 year, 73% at 2 years, and 90% at 5 years in one study [25] . Similarly, in the GRACE registry, in-hospital mortality and clinical outcomes at 6 months (death, recurrent infarction, or unplanned hospital readmission) after an ACS were significantly worse among dialysis patients compared with nondialysis patients [24] . Diagnosis ACS diagnosis may be challenging in dialysis patients [22] . Chest pain is absent on admission in more than 50% of dialysis patients who present with an ACS, likely due to autonomic or uremic neuropathy [26, 27] . Interpretation of troponin values may also be problematic because these patients frequently have elevated troponin levels in the absence of clinical ischemia, significantly affecting the specificity for the diagnosis of acute infarction [28] . Nevertheless, elevated troponin levels in CKD patients with or without suspected ACS are associated with higher risk for subsequent major adverse cardiovascular events [28,29 & ]. For the diagnosis of ACS among dialysis patients, the National Academy of Clinical Biochemistry recommends a dynamic increase in troponin levels of more than 20% within 9 h and at least one value exceeding the 99th percentile [30] . Clearly a high index of suspicion may be necessary to avoid missing the diagnosis of ACS in this population.
Management
Secondary preventive measures, as use of aspirin, angiotensin-converting enzyme inhibitors, b-blockers, or statins, are not applied in the majority of dialysis patients [31, 32] . Coronary angiography and coronary revascularization are also underutilized across the spectrum of CKD, possibly in an attempt to avoid contrast-induced nephrotoxicity, an approach referred to as renalism [33] [34] [35] . However, conservative approaches appear to be associated with a significantly higher 1-year mortality [34] . Although confounding by indication cannot be ruled out in the majority of retrospective analyses, it seems reasonable to treat ACS in dialysis patients according to the standard guidelines used for nondialysis patients (Table 1 ) [22] .
Myocardial revascularization
There is only one RCT comparing myocardial revascularization, either percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG), with medical treatment in ESRD [36] . The primary outcome, unstable angina, MI, or cardiac death occurred in 10/13 medically treated patients (three deaths) and 2/13 revascularized patients (no deaths) (P ¼ 0.002). However, both medical therapy and revascularization techniques have radically changed in the decades since this small study was published raising questions about its contemporary relevance. The ISCHEMIA-CKD Trial (NCT01985360) may provide answers about the optimal strategy for treatment of atherosclerotic coronary disease in patients with advanced CKD.
One caveat is that the majority of new techniques have not been tested in the dialysis population. Drug-eluting stents, for example, hold promise as an alternative to surgical revascularization or bare metal stents, but retrospective analyses are inconclusive about their benefits in uremia. For example, in a propensity-score-matched cohort, 2-year mortality, MI, and target vessel revascularization rates were similar with both types of stents [37] . Similarly, there is no RCT directly comparing CABG with PCI in ESRD. Nevis et al. [38] systematically reviewed 17 retrospective cohort studies conducted between 1977 and 2002. Although significant heterogeneity was identified, CABG was associated with a higher short-term mortality (30 days or in hospital) compared with PCI (10.6 vs. 5.4%, P < 0.001). However, CABG was superior to PCI for long-term mortality (at least 1 year: 51.6 vs. 59.5%, P ¼ 0.01) and other cardiac events (defined as MI or repeat revascularization) [38] . Although many of the included studies were completed prior to the adoption of modern practice patterns, a second meta-analysis, published in 2011 and including three more recent trials, yielded similar results [39] . Registry data in the United States (1997-2009) and the CREDO-Kyoto registry in Japan (2005) (2006) (2007) have also confirmed the superiority of CABG to PCI for long-term clinical outcomes in dialysis patients, especially for multivessel procedures [40, 41] . Given the absence of randomized data, the very high perioperative risks of surgical revascularization in dialysis patients (surgical mortality rates may exceed 10% [42] ), and the high overall mortality rates in the dialysis population, an individualized, patient-centered approach should be considered. CABG may not be the best option in those with significant comorbidities who are not expected to live long enough to reap a long-term benefit from CABG either due to comorbidities or perioperative risk. These patients may be better with medical therapy or percutaneous options. Conversely, otherwise healthy patients may be best treated with CABG [43] .
HEART FAILURE IN END-STAGE RENAL DISEASE
Patients with ESRD have a high incidence of structural heart disease [44] . However, heart failure in dialysis patients is poorly characterized and not optimally treated because the dialytic cycle of volume accumulation between sessions and intradialytic extracorporeal ultrafiltration mask the clinical presentation of the underlying heart disease. In an attempt to classify heart failure in ESRD, the Acute Dialysis Quality Initiative XI Workgroup proposed a functional classification system based on the echocardiographic evidence of heart disease and the impact of renal replacement therapy (RRT) or ultrafiltration on symptoms. The classification is based on the New York Heart Association functional classes and divides each class into subgroups depending on whether symptoms persist or not after RRT [44] . This approach helps differentiate patients who present with volume overload in the absence of underlying cardiomyopathy from those who develop symptoms secondary to an underlying heart condition. To differentiate between patients with diastolic dysfunction and those with pure volume overload, the authors suggest assessing right atrial pressures by inferior vena cava imaging before and after ultrafiltration [44] .
LV hypertrophy is the major mechanism of diastolic dysfunction in CKD. Other mechanisms implicated in the pathogenesis of diastolic dysfunction in ESRD patients include myocardial fibrosis, activation of the intracardiac renin-angiotensin system, anemia, or hyperphosphatemia [45] . A detailed description of the pathophysiology of heart failure in ESRD is beyond the scope of this article but has been reviewed elsewhere [46] .
Heart failure is associated with significant morbidity in dialysis patients. A Canadian cohort found that heart failure is the most common reason for emergency department visit in hemodialysis patients recently discharged from the hospital [47 & ]. Volume overload, as identified with assessment of interdialytic weight gain, has been associated with all-cause and cardiovascular mortality after multivariate adjustment for demographics, inflammation, and malnutrition [48] . Conversely, data from the HEMO study showed that ultrafiltration rates exceeding 13 ml/kg/h are associated with higher all-cause or cardiovascular mortality compared with ultrafiltration rates up to 10 ml/kg/h, despite presumably better treatment of congestion [49] . The mechanism underlying this observation could be repetitive occult myocardial injury. Rapid fluid removal from the intravascular compartment could acutely reduce the effective circulating volume and cause transient myocardial ischemia and myocardial stunning. The long-term impact of repetitive myocardial stunning events on ventricular function may ultimately outweigh the shortterm benefits of improved ultrafiltration [49] .
Finally, it is well known that high-output heart failure is occasionally associated with the creation of an arteriovenous fistula, particularly in those with limited myocardial function reserve [50] . Whether more subtle effects on ventricular function occur in the majority of patients with venous accesses is an unsolved question. In patients with preexisting congestive heart failure, careful estimation of the myocardial functional reserve before fistula creation may be advisable.
ATRIAL FIBRILLATION AND STROKE RISK IN DIALYSIS PATIENTS
Atrial fibrillation is a common arrhythmia in dialysis patients. Its prevalence was estimated to be 10.7% in 2006 and had significantly risen between 1992 and 2006 [51] . The absolute number of hemodialysis patients with atrial fibrillation increased from 3620 patients in 1992 to 23 893 patients in 2006, also reflecting the increasing prevalence of ESRD in the US population. The incidence of atrial fibrillation similarly increased from 11.3% of incident dialysis patients in 1995 to 14.5% in 2007 [52] . This study used Medicare data and enrolled only patients aged 67 years or more. Preliminary results from the MiD trial showed that up to 40% of individuals without known atrial fibrillation at baseline had atrial fibrillation detected with an implantable loop recorder during follow-up [53] . Therefore, atrial fibrillation may be even more common but underdiagnosed in the dialysis population.
Atrial fibrillation is associated with significant morbidity and mortality. One-year mortality rates were significantly higher in dialysis patients with atrial fibrillation compared with those without (hazard ratio 1.72 after adjustment for age, sex, and race) [51] . ESRD patients are at increased risk of stroke compared with the general population (relative risk of 4.4-9.7) [54] . The excess risk of embolic stroke attributable to atrial fibrillation in ESRD patients was found to be six strokes per 1000 patient-years [55] . In a Taiwan nationwide cohort study, the incidence of ischemic stroke increased with higher CHADS 2 and CHA 2 DS 2 -VASc scores (C-statistic of 0.608 and 0.682, respectively) [56] . Unfortunately, whether warfarin is protective against embolic stroke in patients with atrial fibrillation and ESRD remains unclear. No RCTs exist directly comparing vitamin K antagonists with placebo in dialysis patients. Evidence comes from several well conducted cohort studies that are summarized in Table 2 ] also demonstrated how difficult it is to keep hemodialysis patients on warfarin, as more than two-thirds discontinued the drug during the first year. The American Heart Association and American College of Cardiology guideline for the management of patients with atrial fibrillation still recommends warfarin for dialysis patients with a CHA 2 DS 2 -VASc score of more than 1 (class IIa) [63] . However, in the absence of randomized data, and given the conflicting results of the cohort studies, routine anticoagulation of all dialysis patients with atrial fibrillation cannot be unequivocally recommended. Better data are sorely needed. In the meantime, an individualized approach should be considered taking into account the stroke and bleeding risks and the patient's preference.
All the clinical trials with the novel anticoagulants have excluded patients with ESRD. However, given their pharmacological profile, apixaban, and potentially rivaroxaban, could theoretically be considered with some dose adjustment, as they are not primarily renally excreted [64 & ]. However, experience with these medications in dialysis is minimal, and more evidence is required before such a recommendation can be made.
CONCLUSION
Cardiovascular morbidity and mortality remain exceedingly common in dialysis patients. Despite recent progress in the understanding of cardiovascular disease in patients with advanced renal failure, its pathophysiology has not been fully elucidated. The global burden from cardiovascular disease in ESRD is expected to rise given the population aging, and the increasing prevalence of diabetes and hypertension in the general population. Current preventive and management strategies are lacking the efficiency demonstrated in patients with preserved renal function. Future research could focus on the impact of optimizing the dialysis prescription with attention to volume and electrolyte management, on the potential role of the novel anticoagulants in patients with atrial fibrillation, and the role of defibrillators in this patient group.
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